Comparison of the Clinicopathological Features in Small Bile Duct and Bile Ductular Type Intrahepatic Cholangiocarcinoma

Yamada, Minoru; Yamamoto, Yusuke; Sugiura, Teiichi; Kakuda, Yuko; Ashida, Ryo; Tamura, Shunsuke; Okamura, Yukiyasu; Ito, Takaaki; Ohgi, Katsuhisa; Nakanuma, Yasuni; Uesaka, Katsuhiko

doi:10.21873/anticanres.13325

Cited by 9 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,30,31 Compared with other iCCAs, including large duct type, CLC predominant tumours, have distinct clinicopathological features, 10,19,24,31,66 but clinical significances of MF-iCCA subtyping remain to be established. 11,55,66 This study showed that an increased CLC component was correlated with a longer postoperative OS time (r = 0.44, P = 0.006) of MF-iCCAs. Conversely, pure SBD tumours had significantly shorter 5-year survival rates than those with (5-100%) CLC pattern, suggesting that the presence of the CLC component could also influence clinical outcomes of MF-iCCAs, as reported in general iCCAs.…”

Section: Discussionmentioning

confidence: 60%

“…[Colour figure can be viewed at wileyonlinelibrary.com] previous reports (50-85%). 10,12,13,18,55 These data indicate that a wide spectrum of tumour cell differentiation could occur during MF-iCCA progression.…”

Section: Discussionmentioning

confidence: 73%

“…1,3,18 Importantly, a pure CLC tumour may progress into an iCCA with a prominent SBD phenotype, changing the clinical course of affected patients. 55,66 Although angiogenesis is considered an essential process for tumour progression, some cancers can obtain blood supply by utilising pre-existing blood vessels in organs, termed 'vessel co-option'. [32][33][34]45 Liver metastases with replacement HGP are shown to vascularise mainly via vessel co-option.…”

Section: Discussionmentioning

confidence: 99%

“…Recent several studies have shown that the CLC subtype is an independent predictor for better clinical outcomes of MF-iCCAs. 55,66 Practically, optimal percentage cut-offs for subtype components to classify MF-iCCA into different categories need to be identified in further studies. However, 18 (29%) and seven (11.3%) cases were of pure SBD and CLC subtypes, respectively, distinguishing these histological subtypes is important.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Diversity in cell differentiation, histology, phenotype and vasculature of mass‐forming intrahepatic cholangiocarcinomas

et al. 2021

Self Cite

View full text Add to dashboard Cite

Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas Aims: Mass-forming intrahepatic cholangiocarcinomas (MF-iCCAs), involving small bile ducts, bile ductules or canals of Hering, remain treated as a single entity. We aimed to examine the diversity in histology, phenotype and tumour vasculature of MF-iCCAs. Methods and results: Based on morphology and immunophenotype, we classified MF-iCCAs into small bile duct (SBD), cholangiolocarcinoma (CLC), ductal plate malformation (DPM) and hepatocellular carcinoma (HCC)-like subtypes. Genetic correlations among the histological subtypes were examined by multi-region tumour sequencing. Vasculatures and other clinicopathological features were compared among tumour groups with various proportions of the histological subtypes in 62 MF-iCCAs. Cases of pure SBD, CLC, DPM and HCC-like subtypes numbered 18 (29%), seven (11.3%), none (0%) and two (3%), respectively; the remaining 35 (56.4%) cases comprised several components. Genetic alterations, isocitrate dehydrogenase (IDH)1/2, KRAS, TP53, polybromo-1 (PBRM1) and BRCA1-associated protein 1 (BAP1), were shared among SBD, CLC, DPM and hepatoid components within a tumour. We uncovered distinct vascularisation mechanisms among SBD, CLC and DPM subtypes with a prominent vessel cooption in CLC tumours. iCCA with a DPM pattern had the highest vascular densities (mean microvascular density,140/mm 2 ; arterial vessel density, 18.3/ mm 2 ). Increased CLC component was correlated with longer overall survival time (r = 0.44, P = 0.006). Pure SBD tumours had a lower 5-year overall survival rate compared with MF-iCCA with CLC pattern (30.5 versus 72.4%, P = 0.011). Conclusions: MF-iCCAs comprise four histological subtypes. Given their sharing some driver gene alterations, indicating they can have a common cell origin, SBD, CLC and DPM subtypes, however, differ in cell differentiation, histology, phenotype or tumour vasculature.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diversity in cell differentiation, histology, phenotype and vasculature of mass‐forming intrahepatic cholangiocarcinomas

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…ICCA phl refers to tumors originating from the large second-order bile ducts and above involving the peribiliary glands (Figure 1). They are composed of a large tubular or papillary proliferation of tall columnar epithelium with extracellular mucin production, often admixed with poorly differentiated carcinoma cells (13)(14)(15)(16). On the other hand, iCCA pps refers to tumors originating from the small bile ducts, such as Herling's duct, which are usually smaller than the segmental branches (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Prognostic analysis of radical resection for iCCAphl and iCCApps: A retrospective cohort study

Jia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroudAt present, there is no definitive conclusion about the relative prognostic factors on intrahepatic cholangiocarcinoma perihilar large duct type (iCCAphl) and iCCA peripheral small duct type (iCCApps).Aim of the studyTo compare the prognoses of two different types of iCCA, and identify the independent risk factors affecting the long-term survival of patients undergoing radical resection for iCCA.MethodsThis study included 89 patients with iCCA who underwent radical resection at the Department of Hepatobiliary Surgery of the East Yard of the Shandong Provincial Hospital between January 2013 and March 2022. According to the tumor origin, these patients were divided into the iCCAphl group (n = 37) and iCCApps group (n = 52). The prognoses of the two groups were compared using Kaplan–Meier analysis, whereas the independent risk factors of their prognoses were identified using Cox univariate and multivariate regression analyses.ResultsIn the iCCApps group, the independent risk factors for overall survival included diabetes history (p = 0.006), lymph node metastasis (p = 0.040), and preoperative carbohydrate antigen 19-9 (p = 0.035). In the iCCAphl group, the independent risk factors for overall survival included multiple tumors (p = 0.010), tumor differentiation grade (p = 0.008), and preoperative jaundice (p = 0.009).ConclusionsAmong the iCCA patients who underwent radical resection, the long-term prognosis of iCCApps maybe better than that of iCCAphl. The prognoses of these two types of iCCA were affected by different independent risk factors.

show abstract

Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review

Akita,

Yanagimoto,

Tsugawa

et al. 2024

Surg Today

View full text Add to dashboard Cite

Comparison of the Clinicopathological Features in Small Bile Duct and Bile Ductular Type Intrahepatic Cholangiocarcinoma

Cited by 9 publications

References 0 publications

Diversity in cell differentiation, histology, phenotype and vasculature of mass‐forming intrahepatic cholangiocarcinomas

Diversity in cell differentiation, histology, phenotype and vasculature of mass‐forming intrahepatic cholangiocarcinomas

Prognostic analysis of radical resection for iCCAphl and iCCApps: A retrospective cohort study

Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review

Contact Info

Product

Resources

About